PVLA — Palvella Therapeutics, Inc. stock price, charts and financials

Latest market price

151.99

+11.21+7.96%

Overview Short InterestFilings

PVLAQT67Palvella Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

151.99+7.96%

Filing

Up 8.0% — Filed an 8-K material-event report (2026-08-04) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

SLS+5.26%$11.81 VERA-7.07%$29.95 NUVB+4.55%$6.44 HRMY+8.93%$38.78 SION+1.38%$49.94 ZLAB+1.71%$18.49 BCRX+2.38%$9.02 BHVN+2.84%$13.75

Snapshot

Index	-	P/E	-	EPS (ttm)	-21.79	Insider Own	13.13%	Shs Outstand	14.34M	Perf Week	6.41%

Market Cap	2.18B	Forward P/E	-	EPS next Y	-6.54	Insider Trans	-1.01%	Shs Float	9.58M	Perf Month	8.32%

Enterprise Value	2.13B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	22.73%	Perf Quarter	19.11%

Income	-25.00M	P/S	50.70	EPS this Y	74.67%	Inst Trans	-	Short Ratio	8.39	Perf Half Y	90.23%

Sales	43.00M	P/B	55.90	EPS next Y	-18.46%	ROA	-18.69%	Short Interest	2.18M	Perf YTD	45.21%

Book/sh	2.72	P/C	34.06	EPS next 5Y	-	ROE	-56.87%	52W High	161.38 -5.82%	Perf Year	315.84%

Cash/sh	4.46	P/FCF	-	EPS past 3/5Y	-	ROIC	-17.89%	52W Low	36.00 322.19%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	7.72% 7.56%	Perf 5Y	-

Dividend TTM	-	EV/Sales	49.58	EPS Y/Y TTM	-178.29%	Oper. Margin	0.00%	ATR (14)	10.93	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	28.88	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	56.72	Recom	1.92

Dividend Gr. 3/5Y	-	Current Ratio	28.88	EPS Q/Q	45.21%	SMA20	5.02%	Beta	1.68	Target Price	232.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	16.16%	Rel Volume	1.05	Prev Close	140.78

Employees	29	LT Debt/Eq	0.27	Earnings	Nov 17	SMA200	37.91%	Avg Volume	266.31K	Price	151.99

IPO Date	Jan 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-28.34% -	Net Debt/EBITDA	5.63	Volume	279,027	Change	7.96%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-22-26	Reiterated	H.C. Wainwright	Buy	$255 → $270
May-12-26	Initiated	Stephens	Overweight	$220
Feb-24-26	Reiterated	Truist Financial	Buy	$190 → $210
Feb-24-26	Reiterated	Stifel Nicolaus		$180 → $250
Feb-24-26	Reiterated	HC Wainwright & Co.	Buy	$200 → $255
Feb-24-26	Reiterated	Chardan Capital	Buy	$174 → $210
Jan-07-26	Initiated	Mizuho	Outperform	$205
Dec-16-25	Reiterated	Raymond James	Strong Buy	$143 → $193
Dec-16-25	Reiterated	Canaccord Genuity	Buy	$90 → $204
Dec-15-25	Reiterated	UBS		$143

Latest News

Aug-04-26

Aug-04-2603:50PM

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcriptseekingalpha.com

01:05PM

Palvella Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

07:30AM

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com

Aug-01-26

Aug-01-2604:11AM

Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLAdefenseworld.net

Jul-30-26

Jul-30-2607:30AM

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposingglobenewswire.com

Jul-28-26

Jul-28-2607:30AM

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026globenewswire.com

Jul-22-26

Jul-22-2603:47AM

Fifth Third Bancorp Invests $2.49 Million in Palvella Therapeutics, Inc. $PVLAdefenseworld.net

Jul-21-26

Jul-21-2610:37AM

Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On TuesdayBenzinga

Jun-30-26

Jun-30-2607:30AM

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directorsglobenewswire.com

Jun-29-26

Jun-29-2607:30AM

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformationsglobenewswire.com

Jun-27-26

Jun-27-2612:11PM

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rallyfool.com

Jun-22-26

Jun-22-2607:36AM

Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic MalformationsBenzinga

Company

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	43	0	0	0	26	31
Cost of Goods Sold Incl. D&A	3	0	0	0	3	2
Gross Profit	40	0	0	0	23	29
Selling, General and Administrative Excl. Other	16	16	6	3	16	17
Research and Development	41	23	8	9	50	64
Other Operating Expense	0	0	0	0	1	0
Operating Income	-16	-39	-14	-12	-43	-52
Interest Expense	0	6	4	0	0	0
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	-9	3	1	31	10	6
Net Income Before Taxes	-25	-42	-17	19	-33	-46
Income Taxes	0	0	0	0	0	0
Consolidated Net Income	-25	-42	-17	19	-33	-46
Net Income From Continuing Operations	-25	-42	-17	19	-33	-46
Net Income	-25	-42	-17	19	-33	-46
EPS (Recurring)	-21.80	-3.71	-7.83	14.74	-29.61	-56.69
EPS (Basic, Before Extraordinaries)	-21.80	-3.71	-7.83	14.74	-29.61	-56.69
EPS (Diluted)	-21.79	-3.71	-7.83	14.74	-29.61	-56.69
EBITDA	-23	-36	-13	19	-30	-43
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—
Price To Sales Ratio	3.53	—	—	—	—	—
Gross Margin	93.02	—	—	—	88.46	93.55
Operating Margin	-37.21	—	—	—	-165.38	-167.74
Net Margin	-58.14	—	—	—	-126.92	-148.39
Shares Outstanding	1	11	2	1	1	1
Market Capitalization	152	1,151	24	—	—	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goin Kathleen	Chief Operating Officer	Jul 15 '26	Option Exercise	8.11	4,302	34,884	4,302	Jul 17
Goin Kathleen	Chief Operating Officer	Jul 15 '26	Sale	149.28	4,302	642,191	0	Jul 17
Goin Kathleen	Chief Operating Officer	Jun 17 '26	Option Exercise	8.11	4,302	34,884	4,302	Jun 22
Goin Kathleen	Chief Operating Officer	Jun 17 '26	Sale	110.73	4,302	476,373	0	Jun 22
Korenberg Matthew E	CFO, Treasurer	Jun 12 '26	Option Exercise	13.60	1,000	13,600	1,000	Jun 16
Goin Kathleen	Chief Operating Officer	May 20 '26	Option Exercise	8.11	4,302	34,884	4,302	May 22
Goin Kathleen	Chief Operating Officer	May 20 '26	Sale	110.56	4,302	475,631	0	May 22
Goin Kathleen	Chief Operating Officer	Apr 15 '26	Option Exercise	8.11	4,302	34,884	4,302	Apr 17
Goin Kathleen	Chief Operating Officer	Apr 15 '26	Sale	127.24	4,302	547,399	0	Apr 17
JENKINS GEORGE M	Director	Mar 30 '26	Buy	112.30	445	49,974	187,616	Apr 01
Goin Kathleen	Chief Operating Officer	Mar 18 '26	Option Exercise	8.11	4,302	34,884	4,302	Mar 20
Goin Kathleen	Chief Operating Officer	Mar 18 '26	Sale	117.99	4,302	507,611	0	Mar 20
JENKINS GEORGE M	Director	Feb 27 '26	Buy	125.00	4,000	500,000	187,171	Mar 02
HERON ELAINE J	Director	Feb 27 '26	Buy	125.00	2,400	300,000	47,812	Mar 02
Goin Kathleen	Chief Operating Officer	Feb 18 '26	Option Exercise	8.11	4,302	34,884	4,302	Feb 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.